Metabolic Solutions Development Co.

Target - mTOT

Insulin sensitizing compounds exert important metabolic effects on mitochondrial metabolism that involve many key control points for metabolism. Many of these effects have been shown by other investigators. MSDC has identified a novel molecular target through which insulin sensitizers work to treat type 2 diabetes by selectively modulating mitochondrial control of certain metabolic-signaling and nutrient-sensing pathways resulting in improved insulin action without fluid retention or weight gain. Developed to treat type 2 diabetes at its root cause, MSDCs new drug compounds have beneficial effects on the constellation of symptoms that are normally associated with insulin resistance: elevated blood glucose, insulin, triglycerides, and blood pressure. Importantly, this pharmacology includes elevation of HDL, the good cholesterol.

Moreover, several recent studies have shown that a special fat, a so-called "good fat", exists in some adult humans. The amount of brown fat (also called "BAT" for brown adipose tissue) is inversely proportioned to body weight (and white fat). This tissue is brown in color because it is loaded with mitochondria and designed to burn rather than store fat. MSDC compounds favor the development of brown fat in animal models and human cells in tissue culture. Studies are underway to see if the Companys clinical candidates will also increase the amount of brown fat in human patients and if this contributes to positive effects on body weight.